Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

adrian pharmaceuticals, llc - chlorhexidine gluconate (unii: mor84mud8e) (chlorhexidine - unii:r4ko0dy52l) - chlorhexidine gluconate 2.5 mg - periochip is indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. periochip may be used as a part of a periodontal maintenance program, which includes good oral hygiene and scaling and root planing. periochip should not be used in any patient who has a known sensitivity to chlorhexidine.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

dexcel pharma technologies ltd. - chlorhexidine gluconate (unii: mor84mud8e) (chlorhexidine - unii:r4ko0dy52l) - chlorhexidine gluconate 2.5 mg - periochip is indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. periochip may be used as a part of a periodontal maintenance program, which includes good oral hygiene and scaling and root planing. periochip should not be used in any patient who has a known sensitivity to chlorhexidine.

Սինգապուր - անգլերեն - HSA (Health Sciences Authority)

apex pharma marketing pte. ltd. - chlorhexidine digluconate - liner, dental - 2.50 mg - chlorhexidine digluconate 2.50 mg

Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

dexcel pharma gmbh - chlorhexidine gluconate - periodontal insert - 2.5 milligram(s) - antiinfectives and antiseptics for local oral treatment; chlorhexidine

Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

dexcel-pharma limited - chlorhexidine gluconate - dental insert - 2.5 milligram - chlorhexidine

Իսրայել - անգլերեն - Ministry of Health

dexcel pharma technologies ltd - chlorhexidine digluconate - chip - chlorhexidine digluconate 2.5 mg - chlorhexidine - chlorhexidine - the perio- chip is indicated for reduction and/or elimination of pathogenic periodontal pocket microbiota, delaying and/or arresting recolonization of the subgingival microflora, reduction and/or elimination of inflammatory lesions in the periodontal pockets, and as an adjunct to mechanical treatment in periodontitis.

Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

novartis europharm limited - canakinumab - cryopyrin-associated periodic syndromes; arthritis, juvenile rheumatoid; arthritis, gouty - interleukin inhibitors, - periodic fever syndromesilaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:cryopyrin-associated periodic syndromesilaris is indicated for the treatment of cryopyrin-associated periodic syndromes (caps) including:muckle-wells syndrome (mws),neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca),severe forms of familial cold autoinflammatory syndrome (fcas) / familial cold urticaria (fcu) presenting with signs and symptoms beyond cold-induced urticarial skin rash.tumour necrosis factor receptor associated periodic syndrome (traps)ilaris is indicated for the treatment of tumour necrosis factor (tnf) receptor associated periodic syndrome (traps).hyperimmunoglobulin d syndrome (hids)/mevalonate kinase deficiency (mkd)ilaris is indicated for the treatment of hyperimmunoglobulin d syndrome (hids)/mevalonate kinase deficiency (mkd).familial mediterranean fever (fmf)ilaris is indicated for the treatment of familial mediterranean fever (fmf). ilaris should be given in combination with colchicine, if appropriate.ilaris is also indicated for the treatment of:still’s diseaseilaris is indicated for the treatment of active still’s disease including adult-onset still’s disease (aosd) and systemic juvenile idiopathic arthritis (sjia) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (nsaids) and systemic corticosteroids. ilaris can be given as monotherapy or in combination with methotrexate.gouty arthritisilaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (nsaids) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.

Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

regeneron uk limited - rilonacept - cryopyrin-associated periodic syndromes - immunosuppressants - rilonacept regeneron is indicated for the treatment of cryopyrin-associated periodic syndromes (caps) with severe symptoms, including familial cold auto-inflammatory syndrome (fcas) and muckle-wells syndrome (mws), in adults and children aged 12 years and older.

Իսրայել - անգլերեն - Ministry of Health

novartis israel ltd - canakinumab - solution for injection - canakinumab 150 mg / 1 ml - canakinumab - ►periodic fever syndromesilaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:cryopyrin-associated periodic syndromes (caps)ilaris is indicated for the treatment of cryopyrin-associated periodic syndromes (caps) in adults, adolescents and children aged 2 years and older with body weight of 7.5 kg or above, including:• muckle-wells syndrome (mws),• neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca),• severe forms of familial cold autoinflammatory syndrome (fcas) / familial cold urticaria (fcu) presenting with signs and symptoms beyond cold-induced urticarial skin rash.►tumour necrosis factor receptor associated periodic syndrome (traps)ilaris is indicated for the treatment of tumour necrosis factor (tnf) receptor associated periodic syndrome (traps).►hyperimmunoglobulin d syndrome (hids)/ mevalonate kinase deficiency (mkd)ilaris is indicated for the treatment of hyperimmunoglobulin d syndrome (hids)/ mevalonate kinase deficiency (mkd).►familial mediterranean fever (fmf)ilaris is indicated for the treatment of familial mediterranean fever (fmf) in patients in whom colchicine is contraindicated, is not tolerated, or does not provide an adequate response despite the highest tolerable dose of colchicine.ilaris can be given as monotherapy or in combination with colchicine.ilaris is also indicated for the treatment of:►still’s diseaseilaris is indicated for the treatment of active still’s disease including adult-onset still’s disease (aosd) and systemic juvenile idiopathic arthritis (sjia) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (nsaids) and systemic corticosteroids. ilaris can be given as monotherapy or in combination with methotrexate.►gouty arthritisilaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (nsaids) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate

Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - anakinra - arthritis, rheumatoid; covid-19 virus infection - immunosuppressants - rheumatoid arthritis (ra)kineret is indicated in adults for the treatment of the signs and symptoms of ra in combination with methotrexate, with an inadequate response to methotrexate alone.covid-19kineret is indicated for the treatment of coronavirus disease 2019 (covid-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (supar) ≥ 6 ng/ml.periodic fever syndromeskineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:cryopyrin-associated periodic syndromes (caps)kineret is indicated for the treatment of caps, including:neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca)muckle-wells syndrome (mws)familial cold autoinflammatory syndrome (fcas)familial mediterranean fever (fmf)kineret is indicated for the treatment of familial mediterranean fever (fmf). kineret should be given in combination with colchicine, if appropriate.still’s diseasekineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of still’s disease, including systemic juvenile idiopathic arthritis (sjia) and adult-onset still’s disease (aosd), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (nsaids) or glucocorticoids.kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (dmards).